Molecular imaging in oncology: Common PET/CT radiopharmaceuticals and applications

Elisa Franquet, Hyesun Park, Elisa Franquet, Hyesun Park

Abstract

PET/CT is a commonly used modality in cancer imaging, as it can help in diagnosis, staging and assessment of treatment response in many cancer types. A better understanding of the tumor microenvironment and identification of multiple selective targets are promoting further investigation into different radiotracers for diagnosis and therapy. In the past few decades many radiopharmaceuticals have emerged for specific oncologic indications providing superior detection rate than some morphologic modalities. The purpose of this review is to provide an update on the most current radiopharmaceuticals used in cancer imaging including the mechanism of action, indications and pitfalls.

Keywords: Oncology; PET/CT (Positron Emission Tomography/Computed Tomography); Radiopharmaceutical; Radiotracers.

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

© 2022 Published by Elsevier Ltd.

Figures

Fig. 1
Fig. 1
Detection of metastasis on 18F-FDG PET/CT not otherwise seen on CT. 63-year-old woman presenting with left upper lobe mass. (A) Maximum-intensity-projection image (MIP) shows intense 18F-FDG uptake in the left upper lobe (solid arrow) and mediastinal nodes (dashed arrow) as well as focal liver uptake and uptake in the left shoulder. Axial fused PET/CT and CT images of the upper abdomen (B) and upper chest (C) show 18F-FDG-avid hepatic lesion (white arrow) and multiple osseous lesions in the left scapula (blue arrows) and thoracic vertebral body, which were not visualized on CT.
Fig. 2
Fig. 2
Evaluation of Lymphoma with 18F-FDG PET/CT. 43-year-old woman with recent diagnosis of Hodgkin’s Lymphoma, nodular sclerosis subtype. Baseline 18F-FDG PET/CT is shown. (A) Maximum-intensity-projection image (MIP), axial PET, fused PET/CT and CT (B) through the upper chest and (C) upper abdomen. Multistation intensely 18F-FDG-avid lymph nodes in the left axilla (dashed arrow), mediastinum (solid arrow) and retroperitoneum (blue arrow), as well as multiple 18F-FDG-avid foci of uptake in the spleen without CT correlate in non-enhanced CT (asterisk). Diffuse bone marrow uptake in the axial and appendicular skeleton is better appreciated in the MIP images, may indicate bone marrow involvement in the absence of ongoing treatment or be reactive to systemic process (bone marrow biopsy is needed). Physiologic uptake in the liver, brain, bowel, kidneys and breast tissue.
Fig. 3
Fig. 3
Metabolic pattern of 18F-FDG suggesting transformation to high-grade lymphoma. 49-year-old woman with recently diagnosed stage I-II follicular lymphoma on an excisional biopsy of a left axillary lymph node. Patient presented with new acute onset abdominal pain and underwent evaluation with 18F-FDG PET/CT. (A and B) MIP and coronal fused PET/CT shows extensive 18F-FDG-avid disease including lymphadenopathy above and below the diaphragm and involvement of the liver, stomach, left kidney, bladder, uterus, multiple muscles and left clavicle involvement. High intensity of 18F-FDG uptake (SUVmax 22) is discordant with finding on pathology. 18F-FDG pattern of uptake is consistent with transformed follicular lymphoma to a high-grade lymphoma.
Fig. 4
Fig. 4
Systemic evaluation of neuroendocrine tumors expressing somatostatin receptors. 71-year-old woman with SDHD mutation and multiple paragangliomas. (A) MIP image demonstrates increased 68Ga-DOTATATE uptake at multiple soft tissue lesions. Axial PET, CT and fused PET/CT in the (B) skull base (right glomus vagale), (C) pericardial recess and (D) tail of the pancreas in the left upper quadrant consistent with paragangliomas expressing somatostatin receptors.
Fig. 5
Fig. 5
Neuroendocrine tumor imaging and pitfalls. 68Ga-DOTATATE PET/CT in a patient with metastatic neuroendocrine tumor. (A) MIP shows multiple foci of increased radiotracer uptake in lymph nodes of the mediastinum, left supraclavicular region, upper and lower abdomen as well as many hepatic metastases. Faint 68Ga-DOTATATE uptake projecting in the left lower skull (solid arrow) corresponds to a partially calcified extra-axial lesion in the left posterior skull seen on fused PET/CT and CT (B and C). Subsequent MRI shows signal characteristics compatible with meningioma on T2 fat-sat and post-contrast T1 (D and E).
Fig. 6
Fig. 6
Peritoneal carcinomatosis with 18F-FDG and 18F-FAPI-04 PET/CT. (Reprinted, with permission from Ref. [42]). (A) 18F-FDG PET maximum-intensity-projection image demonstrates focal uptake in the region of cecum and transverse colon and possible diffuse peritoneal disease. (B) Corresponding 18F-FAPI-04 PET maximum-intensity projection clearly demonstrates diffuse peritoneal disease including involvement of subphrenic spaces. These images were originally published in JNM. Rodney J. Hicks et al. J Nucl Med 2021;62:296–302 © SNMMI .
Fig. 7
Fig. 7
Evaluation of gastric cancer with 18F-FAPI PET/CT. Gastric cancer with node, liver, and brain metastases. (A) 18F-FAPI PET maximum-intensity projection. (B) Necrotic left occipital metastasis on transaxial 18F-FAPI PET. (C) Correlative CT. Adapted. These images were originally published in JNM. Rodney J. Hicks et al. J Nucl Med 2021;62:296–302 © SNMMI
Fig. 8
Fig. 8
18F-FES PET/CT in breast cancer. 18F-FES PET/CT and 18F-FDG PET/CT (performed one week prior) in an 85-year-old woman with newly diagnosed ER+ left breast invasive lobular carcinoma. (A) 18F-FES PET/CT MIP shows the primary lesion in the left breast (black arrowhead) with ipsilateral axillary lymphadenopathy (white arrowhead), right breast masses (white arrow) and multiple bone lesions (black arrows). Note the standard field of view for 18F-FES PET/CT includes the skull vertex for detection of additional bone metastases (black asterisk). Note physiologic biliary excretion of 18F-FES (white asterisk). (C-H) Representative axial fusion images show enhanced 18F-FES uptake in lesions compared to 18F-FDG using similar window level: (C) left axillary levels 1, 2, and 3 lymphadenopathy with SUVmax 32 on 18F-FES and (D) SUVmax 3.3 on 18F-FDG, (E) left third rib with SUVmax 4.3 with 18F-FES and (F) SUVmax 2.5 with 18F-FDG, and (H) right C5 pedicle with SUVmax 5 with 18F-FES without appreciable uptake above background with 18F-FDG (I). There is concordant uptake between 18F-FES and 18F-FDG PET/CT, more so with 18F-FES, suggesting a favorable response to hormone-directed therapies. Courtesy of Lacey McIntosh D.O., M.P.H. (University of Massachusetts Memorial Medical Center).
Fig. 9
Fig. 9
69-year-old male with history of metastatic castration resistant prostate cancer with rising PSA on Cabazitaxel. Rising PSA levels, 4.98 ng/mL in September 2021 and 14.8 ng/mL in April 2022. (A) MIP 18F-DCFPyL PET/CT in October 2021 with multifocal PSMA-avid disease including uptake at the prostate bed (dashed arrows), pelvis nodes and bones of the axial and appendicular skeleton. (B) MIP PET/CT of 68Ga-PSMA-11 (May 2022) shows similar extent of disease. (C) 68Ga-PSMA-11 axial PET and fused PET/CT with focal uptake in the prostate gland at the right apex (dashed arrows). (D) 68Ga-PSMA-11 axial PET and CT showing right pelvic PSMA-avid lymph node.
Fig. 10
Fig. 10
Detection of subcentimeter active prostate disease with PSMA-based radiotracers. 79-year-old man with history of prostate cancer treated with prostatectomy, radiotherapy, and adjuvant androgen deprivation therapy (ADT) with biochemical recurrence and raising PSA levels, 2.02 ng/mL around the time of the scan. (A) MIP 18F-DCFPyL PET/CT and (B and C) axial PET, fused PET/CT and CT through the retroperitoneum show intense focal uptake in the right common iliac nodal station of the pelvis (dashed arrow). (B) 4 mm left para-aortic (blue arrow) and (C) 3 mm retro-aortic lymph nodes (white arrow) that would have not otherwise been detected on conventional imaging due to small size.
Fig. 11
Fig. 11
Non-prostatic lesions with increased PSMA uptake. 71-year-old man with history of metastatic renal cell carcinoma and prostate cancer. (A) Axial CT and fused PET/CT in the upper chest shows increased focal PSMA uptake associated with lytic bone lesions in a right anterior rib (white arrow) and (B) faint lytic lesion in the right scapula (blue arrow), consistent with metastases from renal cell carcinoma.

References

    1. Farwell M.D., Pryma D.A., Mankoff D.A. PET/CT imaging in cancer: current applications and future directions. Cancer. 2014;120(22):3433–3445.
    1. R. Boellaard, R. Delgado-Bolton, W.J. Oyen, F. Giammarile, K. Tatsch, W. Eschner, F.J. Verzijlbergen, S.F. Barrington, L.C. Pike, W.A. Weber, S. Stroobants, D. Delbeke, K.J. Donohoe, S. Holbrook, M.M. Graham, G. Testanera, O.S. Hoekstra, J. Zijlstra, E. Visser, C.J. Hoekstra, J. Pruim, A. Willemsen, B. Arends, J. Kotzerke, A. Bockisch, T. Beyer, A. Chiti, B.J. Krause, M. European Association of Nuclear, FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0, Eur. J. Nucl. Med. Mol. Imaging, vol. 42(no. 2), 2015, pp. 328–54.
    1. Shim S.S., Lee K.S., Kim B.T., Chung M.J., Lee E.J., Han J., Choi J.Y., Kwon O.J., Shim Y.M., Kim S. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. Radiology. 2005;236(3):1011–1019.
    1. van Baardwijk A., Baumert B.G., Bosmans G., van Kroonenburgh M., Stroobants S., Gregoire V., Lambin P., De Ruysscher D. The current status of FDG-PET in tumour volume definition in radiotherapy treatment planning. Cancer Treat. Rev. 2006;32(4):245–260.
    1. Darling G.E., Maziak D.E., Inculet R.I., Gulenchyn K.Y., Driedger A.A., Ung Y.C., Gu C.S., Kuruvilla M.S., Cline K.J., Julian J.A., Evans W.K., Levine M.N. Positron emission tomography-computed tomography compared with invasive mediastinal staging in non-small cell lung cancer: results of mediastinal staging in the early lung positron emission tomography trial. J. Thorac. Oncol. 2011;6(8):1367–1372.
    1. Heo E.Y., Yang S.C., Yoo C.G., Han S.K., Shim Y.S., Kim Y.W. Impact of whole-body (1)(8)F-fluorodeoxyglucose positron emission tomography on therapeutic management of non-small cell lung cancer. Respirology. 2010;15(8):1174–1178.
    1. Ahmed F., Muzaffar R., Fernandes H., Tu Y., Albalooshi B., Osman M.M. Skeletal metastasis as detected by 18F-FDG PET with negative CT of the PET/CT: frequency and impact on cancer staging and/or management. Front. Oncol. 2016;6:208.
    1. S.F. Barrington, N.G. Mikhaeel, L. Kostakoglu, M. Meignan, M. Hutchings, S.P. Müeller, L.H. Schwartz, E. Zucca, R.I. Fisher, J. Trotman, O.S. Hoekstra, R.J. Hicks, M.J. O'Doherty, R. Hustinx, A. Biggi, B.D. Cheson, Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group, J. Clin. Oncol., vol. 32(no. 27), 2014, pp. 3048–58.
    1. B.D. Cheson, R.I. Fisher, S.F. Barrington, F. Cavalli, L.H. Schwartz, E. Zucca, T.A. Lister, A.L. Alliance, G. Lymphoma, G. Eastern Cooperative Oncology, C. European Mantle Cell Lymphoma, F. Italian Lymphoma, R. European Organisation for, G. Treatment of Cancer/Dutch Hemato-Oncology, O. Grupo Espanol de Medula, G. German High-Grade Lymphoma Study, G. German Hodgkin's Study, G. Japanese Lymphorra Study, A. Lymphoma Study, N.C.T. Group, G. Nordic Lymphoma Study, G. Southwest Oncology, I. United Kingdom National Cancer Research, Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification, J. Clin. Oncol., vol. 32(no. 27), 2014, pp. 3059–68.
    1. Barrington S.F., Kirkwood A.A., Franceschetto A., Fulham M.J., Roberts T.H., Almquist H., Brun E., Hjorthaug K., Viney Z.N., Pike L.C., Federico M., Luminari S., Radford J., Trotman J., Fossa A., Berkahn L., Molin D., D'Amore F., Sinclair D.A., Smith P., O'Doherty M.J., Stevens L., Johnson P.W. PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study. Blood. 2016;127(12):1531–1538.
    1. Seam P., Juweid M.E., Cheson B.D. The role of FDG-PET scans in patients with lymphoma. Blood. 2007;110(10):3507–3516.
    1. Noy A., Schoder H., Gonen M., Weissler M., Ertelt K., Cohler C., Portlock C., Hamlin P., Yeung H.W. The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL) Ann. Oncol. 2009;20(3):508–512.
    1. Alessandrino F., DiPiro P.J., Jagannathan J.P., Babina G., Krajewski K.M., Ramaiya N.H., Giardino A.A. Multimodality imaging of indolent B cell lymphoma from diagnosis to transformation: what every radiologist should know. Insights Imaging. 2019;10(1):25.
    1. Hofmann M., Maecke H., Borner R., Weckesser E., Schoffski P., Oei L., Schumacher J., Henze M., Heppeler A., Meyer J., Knapp H. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur. J. Nucl. Med. 2001;28(12):1751–1757.
    1. Wild D., Schmitt J.S., Ginj M., Macke H.R., Bernard B.F., Krenning E., De Jong M., Wenger S., Reubi J.C. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur. J. Nucl. Med. Mol. Imaging. 2003;30(10):1338–1347.
    1. Antunes P., Ginj M., Zhang H., Waser B., Baum R.P., Reubi J.C., Maecke H. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur. J. Nucl. Med. Mol. Imaging. 2007;34(7):982–993.
    1. Deppen S.A., Liu E., Blume J.D., Clanton J., Shi C., Jones-Jackson L.B., Lakhani V., Baum R.P., Berlin J., Smith G.T., Graham M., Sandler M.P., Delbeke D., Walker R.C. Safety and efficacy of 68Ga-DOTATATE PET/CT for diagnosis, staging, and treatment management of neuroendocrine tumors. J. Nucl. Med. 2016;57(5):708–714.
    1. Sanli Y., Garg I., Kandathil A., Kendi T., Zanetti M.J.B., Kuyumcu S., Subramaniam R.M. Neuroendocrine tumor diagnosis and management: (68)Ga-DOTATATE PET/CT. AJR Am. J. Roentgenol. 2018;211(2):267–277.
    1. Jackson T., Darwish M., Cho E., Nagatomo K., Osman H., Jeyarajah D.R. 68Ga-DOTATATE PET/CT compared to standard imaging in metastatic neuroendocrine tumors: a more sensitive test to detect liver metastasis? Abdom. Radiol. 2021;46(7):3179–3183.
    1. Albanus D.R., Apitzsch J., Erdem Z., Erdem O., Verburg F.A., Behrendt F.F., Mottaghy F.M., Heinzel A. Clinical value of (6)(8)Ga-DOTATATE-PET/CT compared to stand-alone contrast enhanced CT for the detection of extra-hepatic metastases in patients with neuroendocrine tumours (NET) Eur. J. Radiol. 2015;84(10):1866–1872.
    1. Kayani I., Bomanji J.B., Groves A., Conway G., Gacinovic S., Win T., Dickson J., Caplin M., Ell P.J. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG. Cancer. 2008;112(11):2447–2455.
    1. Han S., Suh C.H., Woo S., Kim Y.J., Lee J.J. Performance of (68)Ga-DOTA-conjugated somatostatin receptor-targeting peptide PET in detection of pheochromocytoma and paraganglioma: a systematic review and metaanalysis. J. Nucl. Med. 2019;60(3):369–376.
    1. Tan T.H., Hussein Z., Saad F.F., Shuaib I.L. Diagnostic performance of (68)Ga-DOTATATE PET/CT, (18)F-FDG PET/CT and (131)I-MIBG scintigraphy in mapping metastatic pheochromocytoma and paraganglioma. Nucl. Med. Mol. Imaging. 2015;49(2):143–151.
    1. Naswa N., Sharma P., Gupta S.K., Karunanithi S., Reddy R.M., Patnecha M., Lata S., Kumar R., Malhotra A., Bal C. Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary? Clin. Nucl. Med. 2014;39(1):e27–e34.
    1. Garin E., Le Jeune F., Devillers A., Cuggia M., de Lajarte-Thirouard A.S., Bouriel C., Boucher E., Raoul J.L. Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors. J. Nucl. Med. 2009;50(6):858–864.
    1. Ivanidze J., Roytman M., Lin E., Magge R.S., Pisapia D.J., Liechty B., Karakatsanis N., Ramakrishna R., Knisely J., Schwartz T.H., Osborne J.R., Pannullo S.C. Gallium-68 DOTATATE PET in the evaluation of intracranial meningiomas. J. Neuroimaging. 2019;29(5):650–656.
    1. Bashir A., Broholm H., Clasen-Linde E., Vestergaard M.B., Law I. Pearls and pitfalls in interpretation of 68Ga-DOTATOC PET imaging. Clin. Nucl. Med. 2020;45(6):e279–e280.
    1. Hofman M.S., Lau W.F., Hicks R.J. Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics. 2015;35(2):500–516.
    1. Shiga K., Hara M., Nagasaki T., Sato T., Takahashi H., Takeyama H. Cancer-associated fibroblasts: their characteristics and their roles in tumor growth. Cancers. 2015;7(4):2443–2458.
    1. Dendl K., Koerber S.A., Kratochwil C., Cardinale J., Finck R., Dabir M., Novruzov E., Watabe T., Kramer V., Choyke P.L., Haberkorn U., Giesel F.L. FAP and FAPI-PET/CT in malignant and non-malignant diseases: a perfect symbiosis? Cancers. 2021;13(19)
    1. Dvorak H.F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 1986;315(26):1650–1659.
    1. Altmann A., Haberkorn U., Siveke J. The latest developments in imaging of fibroblast activation protein. J. Nucl. Med. 2021;62(2):160–167.
    1. Loktev A., Lindner T., Mier W., Debus J., Altmann A., Jäger D., Giesel F., Kratochwil C., Barthe P., Roumestand C., Haberkorn U., Tumor-Imaging A. Method targeting cancer-associated fibroblasts. J. Nucl. Med. 2018;59(9):1423–1429.
    1. Dendl K., Schlittenhardt J., Staudinger F., Kratochwil C., Altmann A., Haberkorn U., Giesel F.L. The Role of fibroblast activation protein ligands in oncologic PET imaging. PET Clin. 2021;16(3):341–351.
    1. Toullec A., Gerald D., Despouy G., Bourachot B., Cardon M., Lefort S., Richardson M., Rigaill G., Parrini M.C., Lucchesi C., Bellanger D., Stern M.H., Dubois T., Sastre-Garau X., Delattre O., Vincent-Salomon A., Mechta-Grigoriou F. Oxidative stress promotes myofibroblast differentiation and tumour spreading. EMBO Mol. Med. 2010;2(6):211–230.
    1. De Wever O., Demetter P., Mareel M., Bracke M. Stromal myofibroblasts are drivers of invasive cancer growth. Int. J. Cancer. 2008;123(10):2229–2238.
    1. Liu F., Qi L., Liu B., Liu J., Zhang H., Che D., Cao J., Shen J., Geng J., Bi Y., Ye L., Pan B., Yu Y. Fibroblast activation protein overexpression and clinical implications in solid tumors: a meta-analysis. PLoS One. 2015;10(3)
    1. Sharma P., Singh S.S., Gayana S. Fibroblast activation protein inhibitor PET/CT: a promising molecular imaging tool. Clin. Nucl. Med. 2021;46(3):e141–e150.
    1. Kuyumcu S., Sanli Y., Subramaniam R.M. Fibroblast-activated protein inhibitor PET/CT: cancer diagnosis and management. Front. Oncol. 2021;11
    1. Gundogan C., Guzel Y., Can C., Kaplan I., Komek H. FAPI-04 uptake in healthy tissues of cancer patients in (68)Ga-FAPI-04 PET/CT imaging. Contrast Media Mol. Imaging. 2021;2021
    1. Giesel F.L., Kratochwil C., Schlittenhardt J., Dendl K., Eiber M., Staudinger F., Kessler L., Fendler W.P., Lindner T., Koerber S.A., Cardinale J., Sennung D., Roehrich M., Debus J., Sathekge M., Haberkorn U., Calais J., Serfling S., Buck A.L. Head-to-head intra-individual comparison of biodistribution and tumor uptake of (68)Ga-FAPI and (18)F-FDG PET/CT in cancer patients. Eur. J. Nucl. Med. Mol. Imaging. 2021;48(13):4377–4385.
    1. Kratochwil C., Flechsig P., Lindner T., Abderrahim L., Altmann A., Mier W., Adeberg S., Rathke H., Rohrich M., Winter H., Plinkert P.K., Marme F., Lang M., Kauczor H.U., Jager D., Debus J., Haberkorn U., Giesel F.L. (68)Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer. J. Nucl. Med. 2019;60(6):801–805.
    1. Chen H., Pang Y., Wu J., Zhao L., Hao B., Wu J., Wei J., Wu S., Zhao L., Luo Z., Lin X., Xie C., Sun L., Lin Q., Wu H. Comparison of [(68)Ga]Ga-DOTA-FAPI-04 and [(18)F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer. Eur. J. Nucl. Med. Mol. Imaging. 2020;47(8):1820–1832.
    1. Hicks R.J., Roselt P.J., Kallur K.G., Tothill R.W., Mileshkin L. FAPI PET/CT: will it end the hegemony of (18)F-FDG in oncology? J. Nucl. Med. 2021;62(3):296–302.
    1. Wang L., Tang G., Hu K., Liu X., Zhou W., Li H., Huang S., Han Y., Chen L., Zhong J., Wu H. Comparison of (68)Ga-FAPI and (18)F-FDG PET/CT in the evaluation of advanced lung cancer. Radiology. 2022;303(1):191–199.
    1. Komek H., Can C., Guzel Y., Oruc Z., Gundogan C., Yildirim O.A., Kaplan I., Erdur E., Yildirim M.S., Cakabay B. 68)Ga-FAPI-04 PET/CT, a new step in breast cancer imaging: a comparative pilot study with the (18)F-FDG PET/CT. Ann. Nucl. Med. 2021;35(6):744–752.
    1. Dendl K., Koerber S.A., Finck R., Mokoala K.M.G., Staudinger F., Schillings L., Heger U., Rohrich M., Kratochwil C., Sathekge M., Jager D., Debus J., Haberkorn U., Giesel F.L. 68)Ga-FAPI-PET/CT in patients with various gynecological malignancies. Eur. J. Nucl. Med. Mol. Imaging. 2021;48(12):4089–4100.
    1. Koerber S.A., Staudinger F., Kratochwil C., Adeberg S., Haefner M.F., Ungerechts G., Rathke H., Winter E., Lindner T., Syed M., Bhatti I.A., Herfarth K., Choyke P.L., Jaeger D., Haberkorn U., Debus J., Giesel F.L. The role of (68)Ga-FAPI PET/CT for patients with malignancies of the lower gastrointestinal tract: first clinical experience. J. Nucl. Med. 2020;61(9):1331–1336.
    1. Windisch P., Rohrich M., Regnery S., Tonndorf-Martini E., Held T., Lang K., Bernhardt D., Rieken S., Giesel F., Haberkorn U., Debus J., Adeberg S. Fibroblast activation protein (FAP) specific PET for advanced target volume delineation in glioblastoma. Radiol. Oncol. 2020;150:159–163.
    1. Zhao L., Chen S., Lin L., Sun L., Wu H., Lin Q., Chen H. [(68)Ga]Ga-DOTA-FAPI-04 improves tumor staging and monitors early response to chemoradiotherapy in a patient with esophageal cancer. Eur. J. Nucl. Med. Mol. Imaging. 2020;47(13):3188–3189.
    1. Pang Y., Zhao L., Shang Q., Meng T., Feng L., Wang S., Guo P., Wu X., Lin Q., Wu H., Huang W., Sun L., Chen H. Positron emission tomography and computed tomography with [68Ga]Ga-fibroblast activation protein inhibitors improves tumor detection and staging in patients with pancreatic cancer. Eur. J. Nucl. Med. Mol Imaging. 2022;49(4):1322–1337.
    1. Peterson L.M., Mankoff D.A., Lawton T., Yagle K., Schubert E.K., Stekhova S., Gown A., Link J.M., Tewson T., Krohn K.A. Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol. J. Nucl. Med. 2008;49(3):367–374.
    1. Liao G.J., Clark A.S., Schubert E.K., Mankoff D.A. 18F-fluoroestradiol PET: current status and potential future clinical applications. J. Nucl. Med. 2016;57(8):1269–1275.
    1. Chae S.Y., Ahn S.H., Kim S.B., Han S., Lee S.H., Oh S.J., Lee S.J., Kim H.J., Ko B.S., Lee J.W., Son B.H., Kim J., Ahn J.H., Jung K.H., Kim J.E., Kim S.Y., Choi W.J., Shin H.J., Gong G., Lee H.S., Lee J.B., Moon D.H. Diagnostic accuracy and safety of 16alpha-[(18)F]fluoro-17beta-oestradiol PET-CT for the assessment of oestrogen receptor status in recurrent or metastatic lesions in patients with breast cancer: a prospective cohort study. Lancet Oncol. 2019;20(4):546–555.
    1. Evangelista L., Guarneri V., Conte P.F. 18F-fluoroestradiol positron emission tomography in breast cancer patients: systematic review of the literature & meta-analysis. Curr. Radiol. 2016;9(3):244–257.
    1. Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer statistics, 2022. CA Cancer J. Clin. 2022;72(1):7–33.
    1. Fendler W.P., Weber M., Iravani A., Hofman M.S., Calais J., Czernin J., Ilhan H., Saad F., Small E.J., Smith M.R., Perez P.M., Hope T.A., Rauscher I., Londhe A., Lopez-Gitlitz A., Cheng S., Maurer T., Herrmann K., Eiber M., Hadaschik B. Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer. Clin. Cancer Res. 2019;25(24):7448–7454.
    1. Hope T.A., Eiber M., Armstrong W.R., Juarez R., Murthy V., Lawhn-Heath C., Behr S.C., Zhang L., Barbato F., Ceci F., Farolfi A., Schwarzenbock S.M., Unterrainer M., Zacho H.D., Nguyen H.G., Cooperberg M.R., Carroll P.R., Reiter R.E., Holden S., Herrmann K., Zhu S., Fendler W.P., Czernin J., Calais J. Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 imaging trial. JAMA Oncol. 2021;7(11):1635–1642.
    1. Ruan D., Sun L. 68Ga-DOTATATE and 68Ga-PSMA uptake in granulomatous prostatitis. Clin. Nucl. Med. 2022;47(4):359–361.
    1. Chen M.Y., Franklin A., Yaxley J., Gianduzzo T., McBean R., Wong D., Tatkovic A., McEwan L., Walters J., Kua B. Solitary rib lesions showing prostate-specific membrane antigen (PSMA) uptake in pre-treatment staging (68) Ga-PSMA-11 positron emission tomography scans for men with prostate cancer: benign or malignant? BJU Int. 2020;126(3):396–401.
    1. Niaz M.J., Sun M., Skafida M., Niaz M.O., Ivanidze J., Osborne J.R., O'Dwyer E. Review of commonly used prostate specific PET tracers used in prostate cancer imaging in current clinical practice. Clin. Imaging. 2021;79:278–288.
    1. Gusman M., Aminsharifi J.A., Peacock J.G., Anderson S.B., Clemenshaw M.N., Banks K.P. Review of (18)F-fluciclovine PET for detection of recurrent prostate cancer. Radiographics. 2019;39(3):822–841.
    1. Savir-Baruch B., Zanoni L., Schuster D.M. Imaging of prostate cancer using fluciclovine. Urol. Clin. N. Am. 2018;45(3):489–502.
    1. Calais J., Ceci F., Eiber M., Hope T.A., Hofman M.S., Rischpler C., Bach-Gansmo T., Nanni C., Savir-Baruch B., Elashoff D., Grogan T., Dahlbom M., Slavik R., Gartmann J., Nguyen K., Lok V., Jadvar H., Kishan A.U., Rettig M.B., Reiter R.E., Fendler W.P., Czernin J. (18)F-fluciclovine PET-CT and (68)Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol. 2019;20(9):1286–1294.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever